Mabon Securities analyst Jacqueline Siegel produced her first report, an overview of the industry, since returning to Wall Street following her stint as CFO at Isis Pharmaceuticals Inc.
It is clear, she said, that the sector is in chaos. The former H&Q analyst said she isn't convinced that mergers among small firms will occur at a rate sufficient to prevent corporate failures, despite the synergies that could be gained.
Many of the problems that have surfaced among biotech companies in recent years have their genesis in the belief that an understanding of the basic biology of a molecular disease should translate directly into